Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Naltrexone oral

Next Previous
Drug Profile

Naltrexone oral

Alternative Names: Low-dose naltrexone (LDN) - Transparency Life Sciences; Nalorex; Nemexin; Revia

Latest Information Update: 16 Jul 2016

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator DrugAbuse Sciences
  • Developer Transparency Life Sciences
  • Class Analgesics; Cyclopropanes; Drug withdrawal therapies; Eye disorder therapies; Irritable bowel syndrome therapies; Morphinans; Small molecules
  • Mechanism of Action Opioid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Opioid abuse
  • New Molecular Entity No

Highest Development Phases

  • Marketed Alcoholism; Opioid abuse
  • No development reported Crohn's disease

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Crohn's-disease in USA (PO)
  • 15 Mar 2016 Biomarkers information updated
  • 18 Dec 2012 Early research in Crohn's disease in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top